News and Trends 22 May 2023
FDA approves first topical gene therapy for dystrophic epidermolysis bullosa wound treatment
The U.S. Food and Drug Administration has approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and…
